儿童脓毒症的诊断、管理与亚表型
该文综述了儿童脓毒症定义与诊断标准的更新需求、自动化筛查算法与生物标志物组合的辅助作用,以及初始管理(广谱抗菌药物、液体复苏、血管活性药物)和辅助治疗(皮质类固醇等)的进展。精准治疗是未来方向,尤其针对脓毒症诱导的多器官功能障碍综合征和亚表型患儿。
要点
- 自动化筛查算法和生物标志物组合可辅助早期识别脓毒症。
- 初始管理关键:及时广谱抗菌药物、液体复苏和血管活性药物。
核心结论
- 脓毒症和脓毒性休克是儿童重大疾病负担,需要更新定义和诊断标准。
- 自动化筛查和生物标志物组合有助于早期识别,但需平衡早期治疗与避免不必要的广谱抗菌药物和住院。
- 精准治疗是未来方向,尤其针对脓毒症诱导的多器官功能障碍综合征和亚表型患儿。
研究设计与样本
- 本文为综述,未报告具体检索范围或研究方法。
主要发现
- 幸存者面临新发或加重的功能损害风险,包括生活质量下降、新发呼吸、营养或技术辅助需求以及反复严重感染。
- 对脓毒症病理生理学认识的进展提示需要更新儿童脓毒症和脓毒性休克的定义及诊断标准。
- 新数据支持自动化筛查算法和生物标志物组合在辅助早期识别中作用日益增加。
- 皮质类固醇和其他代谢疗法的辅助治疗作用尚未完全明确,正在进行的研究将提供更新指导。
关键数值与推荐
- 一旦怀疑脓毒症或脓毒性休克,及时启动广谱经验性抗菌药物治疗、液体复苏和血管活性药物是初始管理的关键组成部分。
临床怎么用
- 对疑似脓毒症或脓毒性休克的患儿,应及时启动广谱经验性抗菌药物治疗、液体复苏和血管活性药物。
- 可考虑使用自动化筛查算法和生物标志物组合辅助早期识别脓毒症。
- 关注精准治疗策略,尤其对于脓毒症诱导的多器官功能障碍综合征和特定亚表型患儿。
局限性
- 本文为综述,未报告系统检索策略或纳入研究的偏倚风险。
- 皮质类固醇和其他代谢疗法的辅助治疗作用尚未完全明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sepsis and septic shock are major causes of morbidity, mortality, and health care costs for children worldwide, including >3 million deaths annually and, among survivors, risk for new or worsening functional impairments, including reduced quality of life, new respiratory, nutritional, or technological assistance, and recurrent severe infections. Advances in understanding sepsis pathophysiology highlight a need to update the definition and diagnostic criteria for pediatric sepsis and septic shock, whereas new data support an increasing role for automated screening algorithms and biomarker combinations to assist earlier recognition. Once sepsis or septic shock is suspected, attention to prompt initiation of broad-spectrum empiric antimicrobial therapy, fluid resuscitation, and vasoactive medications remain key components to initial management with several new and ongoing studies offering new insights into how to optimize this approach. Ultimately, a key goal is for screening to encompass as many children as possible at risk for sepsis and trigger early treatment without increasing unnecessary broad-spectrum antibiotics and preventable hospitalizations. Although the role for adjunctive treatment with corticosteroids and other metabolic therapies remains incompletely defined, ongoing studies will soon offer updated guidance for optimal use. Finally, we are increasingly moving toward an era in which precision therapeutics will bring novel strategies to improve outcomes, especially for the subset of children with sepsis-induced multiple organ dysfunction syndrome and sepsis subphenotypes for whom antibiotics, fluid, vasoactive medications, and supportive care remain insufficient.
引用
- Weiss SL, Fitzgerald JC. Pediatric Sepsis Diagnosis, Management, and Sub-phenotypes. Pediatrics. 2024. PMID: 38084084. doi:10.1542/peds.2023-062967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。